Abstract:Purpose: To investigate the possibility of using radiofrequency hyperthermia (RFH) to enhance intratumoral therapeutic effect of liposomal doxorubicin on hepatocellular carcinoma (HCC) via an interventional molecular imaging approach. Materials and methods: For both in-vitro confirmation and in-vivo validation, Luciferase/ mCherry-labeled human HCC cells (HepG2) and mice subcutaneous hepatic cancer xenografts were treated by: (i) combination therapy of liposomal doxorubicin plus RFH at 42 degrees C; (ii) liposomal doxorubicin alone; (iii) RFH at 42 degrees C alone; (iv) phosphate buffered saline (PBS) as a control. For in-vitro confirmation, MTS assay, confocal microscopy, optical imaging and flow cytometry were used to evaluate and compare cell viabilities and apoptosis among different treatment groups. For in vivo validation, liposomal doxorubicin was directly injected into the tumor and RFH was performed subsequently under ultrasound imaging guidance. Changes of tumor sizes were quantified using ultrasound imaging and bioluminescence signal intensities after treatments were measured by optical imaging over 14 days, which were correlated with subsequent histology analysis. Results: Of in vitro experiments, MTS assay demonstrated the lowest cell proliferation in combination therapy group compared with the other three groups (25.0 +/- 5.6% vs 49.7 +/- 5.2% vs 94.2 +/- 3.9% vs 100%, respectively, P < 0.001). Flow cytometry showed the highest percentage of early a poptotic HepG2 cells in combination therapy compared to the other three groups (37.9 +/- 3.2% vs 32.2 +/- 1.7% vs 2.9 +/- 1.7% vs 1.8 +/- 0.7%, respectively, P < 0.001). Of in vivo experiments, optical imaging demonstrated a significantly decreased bioluminescence signal intensities in the combination therapy group, compared with the other three groups (0.53 +/- 0.10 VS 1.4 +/- 0.5 VS 2.8 +/- 0.8 VS 3.0 +/- 0.3, P < 0.05). Ultrasound images showed the smallest tumor volumes of the combination therapy group, in comparison to other control groups (0.7 +/- 0.1 VS 1.8 +/- 0.4 VS 3.0 +/- 0.8 VS 3.3 +/- 0.3, P < 0.05). Both histologic correlation confirmed imaging findings. Conclusion: RFH can enhance intratumoral therapy with liposomal doxorubicin for HCC, which is effectively monitored by ultrasound imaging and optical imaging techniques. This concept may provide new avenues for eradicating the residual tumor cells when combining RFA with interventional molecular imaging guided direct intratumoral chemotherapy of HCC.

Evaluation of radioimmunoimaging during radioimmunotherapy with monoclonal anti-human hepatocellular carcinoma antibodies

Radioimmunoimaging of human hepatocellular carcinoma xenografts with 131I-anti-HBx monoclonal antibody

Biodistribution and Localization of Iodine-131-Labeled Metuximab in Patients with Hepatocellular Carcinoma

Human Anti-(Murine Ig) Antibody Responses in Patients with Hepatocellular Carcinoma Receiving Intrahepatic Arterial 131 I-labeled Hepama-1 Mab. Preliminary Results and Discussion

Tumor Radioimmunoimaging of Chimeric Antibody in Nude Mice with Hepatoma Xenograft.

Phase I Clinical Trial of Targeted Therapy Using 131I-Hepama-1 Mab in Patients with Hepatocellular Carcinoma

Radioiodinated Anti-Hepatocellular Carcinoma (HCC) Ferritin Targeting Therapy, Tumor Imaging and Anti-Antibody Response in HCC Patients with Hepatic Arterial Infusion

Enhanced Efficacy of Direct Immunochemotherapy for Hepatic Cancer with Image-Guided Intratumoral Radiofrequency Hyperthermia

Radioimmunotherapy for Hepatocellular Carcinoma (HCC) Using 131I-Anti HCC Isoferritin IgG: Preliminary Results of Experimental and Clinical Studies

Treatment of Hepatocellular Carcinoma by Intratumoral Injection of 125I-AA98 Mab and Its Efficacy Assessments by Molecular Imaging.

INTRAHEPATIC ARTERIAL I-131 ANTI-HEPATOCELLULAR CARCINOMA (HCC) MONOCLONAL-ANTIBODY COMBINED WITH HEPATIC-ARTERY LIGATION FOR TREATMENT OF UNRESECTABLE HCC

Biodistribution and Imaging of Radioiodinate Antihuman Tumor-derived IgG Light Chain Monoclonal Antibody in Nude Mice Bearing Tumor in Vivo

Targeting Radioimmunotherapy of Hepatocellular Carcinoma with Iodine (131I) Metuximab Injection: Clinical Phase I/II Trials

Improved Long-Term Survival for Unresectable Hepatocellular Carcinoma (HCC) with a Combination of Surgery and Intrahepatic Arterial Infusion of 131 I-anti-HCC Mab. Phase I/II Clinical Trials

Dosimetry of 131I labeled metuximab and transarterial chemoembolization for treatment of hepatocellular carcinoma

Orthotopic Hepatocellular Carcinoma: Molecular Imaging-Monitored Intratumoral Hyperthermia-Enhanced Direct Oncolytic Virotherapy

Radioimmunotherapy in Treatment of Unresectable Hepatoma—a Report of 43 Cases

Intratumoral Radiofrequency Hyperthermia-Enhanced Chemotherapy of Liposomal Doxorubicin on Hepatocellular Carcinoma.

Multiple-tumor binding specificity and high tumor uptake of monoclonal antibody 3H11

Radioimmunoimaging of gastric cancer with 1'31I iodine labeled monoclonal antibodies

Radioimmunoimaging and Targeting Treatment in an Immunocompetent Murine Model of Triple-Negative Breast Cancer Using Radiolabeled Anti-Programmed Death-Ligand 1 Monoclonal Antibody